Skip to main content
. 2024 Apr 2;14(8):1440–1456. doi: 10.1158/2159-8290.CD-23-1217

Figure 3.

Figure 3.

Antitumor activity of MET inhibitor in two patients with NSCLC harboring MET TKD mutations. Confirmed partial response achieved with the type Ib MET inhibitor elzovantinib (TPX-0022) in A a 64-year-old man with MET H1094Y mutant lung adenocarcinoma and in B an 80-year-old man with MET F1200I mutant lung adenocarcinoma.